Commercial Expansion With FDA approval of the IsoPSA kit and a new CEO leading commercial expansion, Cleveland Diagnostics is positioned to scale national lab adoption. Target opportunities include CLIA labs, hospital networks, and pathology groups; pursue multi site deployment, distributor partnerships, and reimbursement support.

Prostate Focus Prostate cancer focused IsoPSA and the PSA awareness campaign indicate a strong go to market emphasis in urology and oncology. Opportunities to target urology clinics, cancer centers, and reference labs; create sales collaterals highlighting IsoPSA's clinical utility and offer pilot programs with early adopters.

Funding & Scale A $75M funding round and revenue between 25M and 50M position the company to invest in sales expansion, manufacturing scale, and channel development. Explore enterprise deals with large diagnostics networks, license or partner for broader adoption, and implement volume based pricing or bundled test offerings.

Leadership Momentum Leadership momentum from the appointment of CEO Michael Iskra and new board members signals governance strength and readiness to scale sales efforts and build strategic partnerships globally.

Platform Potential Platform potential from IsoClear's protein structure based approach suggests opportunities to extend beyond IsoPSA into other cancer or diagnostic areas. Consider co development, licensing, or white label partnerships to accelerate broader test development with industry collaborators.